drugset / Trial / NCT03721757
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
Phase 2
Completed
21 enrolled
The Clatterbridge Cancer Centre NHS Foundation Trust
Bristol-Myers Squibb · collabUniversity of Liverpool · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is to investigate the use of nivolumab in sequence with standard of care surgery and radiation/chemoradiation in locally advanced oral cavity Squamous cell carcinoma of the oral cavity.
Timeline
- Start
- 2019-05-10
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |